title: Correlation between oocyte number and follicular fluid concentration of pituitary adenylate cyclase-activating polypeptide (PACAP) in women after superovulation treatment.
abstract: Follicular growth, ovulation, and luteinization are influenced by interactions of peptide and steroid hormone-signaling cascades in the ovary. Pituitary adenylate cyclase-activating polypeptide (PACAP) plays an important role in the regulation of several endocrine processes and is present in ovarian follicular fluid (FF). However, little is known about PACAP in FF with regard to maturation, ovulation, fertilization, and successful pregnancy. The aim of this pilot study was to investigate whether there is a correlation between PACAP concentration in FF and ovarian response to superovulation treatment in infertile women, performed in volunteers (n = 132; aged between 20 and 35). After treatment, the number of harvested oocytes was recorded and PACAP immunoreactivity in FF was measured by radioimmunoassay. All the corresponding PACAP concentrations were below 290 fmol/ml in cases when the number of harvested oocytes exceeded 14 per patient, while in all cases above 290 fmol/ml, the number of oocytes was below 14. Using these cutoff values, we determined three study groups: high-PACAP concentration, high-oocyte number, and low-PACAP concentration-low-oocyte number groups. Median values of PACAP concentration in these groups were 411.2, 106.5, and 101.0 fmol/ml, respectively, while the median values of harvested oocytes were 5.5, 19.0, and 5.0, respectively. Differences were significant, indicating a correlation between concentration of PACAP in FF and the number of recruited oocytes. Higher concentrations of PACAP in FF might be associated with lower number of developing oocytes, while low concentrations of PACAP might correlate with a markedly higher number of ova retrieved, thus predicting a higher chance for ovarian hyperstimulation. Our present study is among the first few human clinical studies with direct conclusions drawn for possible clinical impact of PACAP.
authors.affiliation: Department of Obstetrics and Gynecology, University of Pecs, Clinical Center, Edesanyak Str. 17, 7624 Pecs, Hungary. mkoppan@gmail.com
authors.forename: M
authors.initials: M
authors.lastname: Koppan
authors.forename: A
authors.initials: A
authors.lastname: Varnagy
authors.forename: D
authors.initials: D
authors.lastname: Reglodi
authors.forename: R
authors.initials: R
authors.lastname: Brubel
authors.forename: J
authors.initials: J
authors.lastname: Nemeth
authors.forename: A
authors.initials: A
authors.lastname: Tamas
authors.forename: L
authors.initials: L
authors.lastname: Mark
authors.forename: J
authors.initials: J
authors.lastname: Bodis
mesh_terms: D000328:Adult; D015415:Biomarkers; D002452:Cell Count; D006063:Chorionic Gonadotropin / Q000008:administration & dosage / Q000494:pharmacology; D005260:Female; D043373:Follicle Stimulating Hormone, Human / Q000008:administration & dosage / Q000494:pharmacology; D015571:Follicular Fluid / Q000737:chemistry*; D006801:Humans; D007247:Infertility, Female / Q000503:physiopathology; D009865:Oocytes; D016471:Ovarian Hyperstimulation Syndrome / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology*; D010053:Ovary / Q000187:drug effects; D010865:Pilot Projects; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide / Q000032:analysis* / Q000502:physiology; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology; D013480:Superovulation / Q000502:physiology*; D020858:Tissue and Organ Harvesting; D017329:Triptorelin Pamoate / Q000008:administration & dosage / Q000494:pharmacology; D055815:Young Adult
chemical_list: C495401:ADCYAP1 protein, human; D015415:Biomarkers; D006063:Chorionic Gonadotropin; D043373:Follicle Stimulating Hormone, Human; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide; D011994:Recombinant Proteins; C571801:follitropin alfa; D017329:Triptorelin Pamoate